DK2004204T3 - Behandling af neurodegenerative sygdomme med selenat - Google Patents

Behandling af neurodegenerative sygdomme med selenat

Info

Publication number
DK2004204T3
DK2004204T3 DK07718638.5T DK07718638T DK2004204T3 DK 2004204 T3 DK2004204 T3 DK 2004204T3 DK 07718638 T DK07718638 T DK 07718638T DK 2004204 T3 DK2004204 T3 DK 2004204T3
Authority
DK
Denmark
Prior art keywords
selenate
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Application number
DK07718638.5T
Other languages
English (en)
Inventor
Christopher Hovens
Niall Corcoran
Original Assignee
Velacor Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velacor Therapeutics Pty Ltd filed Critical Velacor Therapeutics Pty Ltd
Application granted granted Critical
Publication of DK2004204T3 publication Critical patent/DK2004204T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK07718638.5T 2006-03-29 2007-03-29 Behandling af neurodegenerative sygdomme med selenat DK2004204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK2004204T3 true DK2004204T3 (da) 2013-01-07

Family

ID=38540722

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07718638.5T DK2004204T3 (da) 2006-03-29 2007-03-29 Behandling af neurodegenerative sygdomme med selenat

Country Status (14)

Country Link
US (2) US8920851B2 (da)
EP (1) EP2004204B1 (da)
JP (1) JP5542430B2 (da)
KR (1) KR101451439B1 (da)
CN (1) CN101478977B (da)
AU (1) AU2007231547B2 (da)
BR (1) BRPI0709033A2 (da)
CA (1) CA2644441C (da)
DK (1) DK2004204T3 (da)
ES (1) ES2394348T3 (da)
MX (1) MX2008012479A (da)
NZ (2) NZ596244A (da)
RU (1) RU2489155C2 (da)
WO (1) WO2007109851A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067008B2 (en) 2004-08-23 2011-11-29 Yeda Research And Development Co. Peptide inhibitors for mediating stress responses
NZ596244A (en) 2006-03-29 2013-05-31 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
JP5616631B2 (ja) * 2006-04-24 2014-10-29 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
US20100247517A1 (en) * 2007-11-22 2010-09-30 Boehringer Ingelheim Internationational GmbH Use of mnk inhibitors for the treatment of alzheimer's disease
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
JP6659050B2 (ja) * 2015-03-26 2020-03-04 スーヂョウ アウゾン バイオロジカル テクノロジー カンパニー， リミテッド Ｐ７５ｅｃｄ及び／又はｐ７５による神経学的障害の診断又は処置方法
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
KR102846956B1 (ko) * 2018-06-29 2025-08-14 리주베나떼 바이오메드 엔브이 노화-관련 질환 및/또는 퇴행성 질환에 사용하는 약제학적 결합물
CA3131402A1 (en) * 2019-03-26 2020-10-01 Xiaoyan Zhao Compositions, methods and systems for protein corona analysis from biofluids and uses thereof
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPH04247033A (ja) * 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
CA2495386C (en) * 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004099168A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
NZ596244A (en) 2006-03-29 2013-05-31 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
WO2007109853A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors

Also Published As

Publication number Publication date
RU2489155C2 (ru) 2013-08-10
WO2007109851A1 (en) 2007-10-04
CA2644441A1 (en) 2007-10-04
CN101478977A (zh) 2009-07-08
EP2004204A1 (en) 2008-12-24
US20090169649A1 (en) 2009-07-02
EP2004204A4 (en) 2010-06-02
NZ596244A (en) 2013-05-31
US20140141104A1 (en) 2014-05-22
JP5542430B2 (ja) 2014-07-09
RU2008142514A (ru) 2010-05-10
JP2009532340A (ja) 2009-09-10
EP2004204B1 (en) 2012-09-12
AU2007231547B2 (en) 2012-07-12
CN101478977B (zh) 2013-03-27
KR101451439B1 (ko) 2014-10-16
US8920851B2 (en) 2014-12-30
CA2644441C (en) 2014-09-09
MX2008012479A (es) 2009-08-13
AU2007231547A1 (en) 2007-10-04
ES2394348T3 (es) 2013-01-30
BRPI0709033A2 (pt) 2011-06-21
KR20090015038A (ko) 2009-02-11
NZ571835A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
DK2182983T3 (da) Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2222272T3 (da) Behandling af luftvejssygdom
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
DK2091673T3 (da) Elektromagnetisk behandling af kontaminerede materialer
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2056858T3 (da) Behandling af lungesygdomstilstande
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0715728A2 (pt) tratamento de distérbio cartilaginosos
DK1981515T3 (da) MAPC behandling af hjerneskader og -sygdomme
DK2022504T3 (da) Salve til behandling af hæmorider
DK2175849T3 (da) Behandling af melanomer
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten